zoledronic acid injection, solution
hospira, inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 100 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl = ca in mg/dl + 0.8 (4.0 g/dl - patient albumin (g/dl)). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. limitations of use the safety and efficacy of zoledronic acid in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adverse reactio
dronalen plus d-cal alendronic acid 70mg/colecalciferol 140 microgram tablet and 1250mg calcium carbonate tablet composite pack
merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -
fosamax plus d-cal alendronic acid 70mg/colecalciferol 140 microgram tablet and 1250mg calcium carbonate tablet composite pack
merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -
zoledronic acid injection
accord healthcare inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl = ca in mg/dl + 0.8 (4.0 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non–tumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [
primene 10% amino acids solution for injection bottle
baxter healthcare pty ltd - threonine, quantity: 3.7 mg/ml; proline, quantity: 3 mg/ml; glycine, quantity: 4 mg/ml; arginine, quantity: 8.4 mg/ml; tyrosine, quantity: 0.45 mg/ml; valine, quantity: 7.6 mg/ml; leucine, quantity: 10 mg/ml; serine, quantity: 4 mg/ml; isoleucine, quantity: 6.7 mg/ml; cysteine, quantity: 1.89 mg/ml; taurine, quantity: 0.6 mg/ml; lysine, quantity: 11 mg/ml; ornithine monohydrochloride, quantity: 3.18 mg/ml; histidine, quantity: 3.8 mg/ml; alanine, quantity: 8 mg/ml; aspartic acid, quantity: 6 mg/ml; methionine, quantity: 2.4 mg/ml; glutamic acid, quantity: 10 mg/ml; tryptophan, quantity: 2 mg/ml; phenylalanine, quantity: 4.2 mg/ml - injection, intravenous infusion - excipient ingredients: malic acid; water for injections - primene 10% amino acid iv infusion is indicated in infants and neonates at term or premature, for short-term use, of normal or low birth-weight when oral or enteral nutrition is impossible, insufficient or contraindicated. it is used as an amino acid component in a composite admixture of total parenteral nutrition.
gaviscon extra mixed berries flavour chewable tablets sodium alginate 250 mg sodium hydrogen carbonate 106.5 mg calcium carbonate 187.5 mg
reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid
zoledronic acid viatris
viatris limited - zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml; - concentrate for infusion - 4 mg/5ml - active: zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml excipient: hydrochloric acid sodium citrate sodium hydroxide water for injection - · treatment of tumour-induced hypercalcaemia.
alendronic acid 10mg tablets
arrow generics limited whiddon valley barnstaple, north devon, ex32 8ns, united kingdom - alendronic acid - tablet - alendronic acid 10 mg - drugs for treatment of bone diseases
zoledronic acid medac
medac gesellschaft für klinische spezialpräparate mbh - zoledronic acid monohydrate - fractures, bone; cancer - drugs for treatment of bone diseases - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.treatment of adult patients with tumour-induced hypercalcaemia (tih).
zoledronic acid accord zoledronic acid 4mg/5ml concentrated injection vial
accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.